Skip to content


Chalazion or Meibomian cyst is the most common inflammatory lesion of the eyelid. It is caused by the non-infective basis obstruction of a meibomian gland. The obstruction produces a build-up of irritating lipidic compounds in surrounding lid tissues with consequent inflammation.

On occasion, a chalazion may enlarge and pass through the tarsal plate to the external part of the eyelid.

Early diagnosis and treatment are essential so that chalazion does not develop chronic complications or evolve in other serious inflammatory lesions such as stye.

Suggested Protocols

High thermal impact and therefore IPL is not to be used. The treatment consist of an application with the standard supply red light mask. Red light stimulates ATP by increasing and improving cellular activity, it reduces inflammation and oedema and works on meibomian glands.


Single usage
Joint usage
Pathology Technology Suggested Protocol
> No. Treatments > Frequency (Days Apart)
Pathology> Chalazion Technology OPE® IPL LM® LLLT
Suggested Protocol > No. Treatments 2 to 4 > Frequency (Days Apart) 4 to 7
Not all treatments can be applied in all countries.

Scientific Coverage

STONECIPHER, Karl; POTVIN, Richard. Low level light therapy for the treatment of recalcitrant chalazia: a sample case summary. Clinical Ophthalmology (Auckland, NZ), 2019, 13: 1727.

Get Started Now
Get in touch to find out how you can benefit from the Espansione Ecosystem of Technologies and Solutions.

In compliance with current regulations, let us know which audience you belong to:

You must fill in the form to download the file.

I want to be updated about Espansione products and services

This field is required.
This field is required.
This field is required.
A valid email address is required.
This field is required.
This field is required.
I have read the privacy policy and the terms and conditions of the site
This field is required.
I want to be updated about Espansione products and services. You can unsubscribe at any time, by using the “unsubscribe” feature at the bottom of any communication you receive.

Thank you for contacting us.